REGISTERED
on 14 Jul 2020
Last Applicant/ Owned by
2nd Floor, 2 Woodberry Grove
London
GB
N120DR
Serial Number
88072409 filed on 09th Aug 2018
Registration Number
6098589 registered on 14th Jul 2020
Filing Basis
1. intent to use
Disclaimer
NO DATA
NANOGENICS
Pharmaceutical and natural remedies for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma, eye diseases, bone diseases, vascular diseases, liver diseases, immune system-related diseases and disorders, and diseases of the brain; medical preparations for use in relation to gene therapy for the treatment of cancer, respiratory d Read More
Classification Information
Class [005]
Pharmaceutical Products
Pharmaceutical and natural remedies for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma, eye diseases, bone diseases, vascular diseases, liver diseases, immune system-related diseases and disorders, and diseases of the brain; medical preparations for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver diseases, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver diseases, immune system-related diseases and disorders, and diseases of the brain; medical preparations being nanoparticles for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations containing siRNA, RNA, shRNA, mRNA or DNA for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver diseases, immune system-related diseases and disorders, and diseases of the brain; pharmaceutical medical preparations being nanoparticles for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals containing siRNA for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals containing shRNA for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals containing mRNA for treatments in the form of gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals containing DNA for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations containing lipids, liposomes or peptides for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals containing lipids, liposomes or peptides for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations for use in gene therapy for the treatment of tumours; biochemical preparations for medical purposes for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; biological preparations for medical purposes for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; reagents for medical use; reagents for use in medical genetic testing; anti-cancer preparations; anti-cancer drugs; compounds for treating cancer; biopharmaceuticals for the treatment of cancer; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-cancer preparations of microbial origin; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations being nanoparticles for the treatment of cancer; pharmaceutical preparations containing siRNA, RNA, shRNA, mRNA or DNA for the treatment of cancer; pharmaceutical products for the treatment of cancer; biological preparations for the treatment of cancer; anti-cancer preparations from hormones and antagonists; pharmaceutical preparations and substances for the prevention of cancer; chemotherapeutics for use in the treatment of cancer; pharmaceutical preparations for use in chemotherapy for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment and prevention of tumours; drug delivery agents in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals ; drug delivery agents being made from lipids, liposomes or peptides in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents that facilitate the delivery of pharmaceutical preparations in the form of nanoparticles; drug delivery agents for use in relation to the delivery of siRNA, shRNA, mRNA, RNA, DNA or other genetic material in the form of nanoparticles; drug delivery agents for use in gene therapy in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents being nanoparticles in the form of an artificial virus that facilitate the delivery of a wide variety of pharmaceuticals; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; none of the aforesaid for use in relation to the treatment of hair loss or hair growth stimulation
Class [042]
Computer & Software Services & Scientific Services
Medical and pharmacological research services all in the field of gene therapy and treatment of cancer; biological research, clinical research and medical research all in the field of gene therapy; research in the field of gene therapy; scientific research for medical purposes in the area of cancerous diseases; pharmaceutical product development; research of pharmaceuticals; research relating to pharmaceutical delivery agents; development of pharmaceutical delivery agents; research and development in the pharmaceutical and biotechnology fields; providing information about the results of clinical trials for pharmaceutical products; scientific research services for assessing the efficiency of pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; development of pharmaceutical preparations and substances; development of pharmaceuticals and pharmaceutical preparations being nanoparticles; development of pharmaceuticals and pharmaceutical preparations containing siRNA, RNA, shRNA, mRNA or DNA; development of drug delivery agents being made from lipids, liposomes or peptides; development of drug delivery agents that facilitate the delivery of pharmaceuticals and pharmaceutical preparations; development of pharmaceutical and drug delivery agents for use in relation to the delivery of siRNA, shRNA, mRNA, RNA, DNA or other genetic material; development of pharmaceuticals and pharmaceutical preparations for use in gene therapy; development of drug delivery agents for use in gene therapy; development of drug delivery agents being nanoparticles; providing consulting to medical research companies in the design and conduct of clinical trials and proving consulting to pharmaceutical companies in the design of pharmaceutical products
Mark Details
Serial Number
No 88072409
Mark Type
No Service Mark
Attorney Docket Number
No 400423-20077
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 14th Jul 2020 | REGISTERED-PRINCIPAL REGISTER |
| 10th Jun 2020 | 1(B) BASIS DELETED; PROCEED TO REGISTRATION |
| 08th Jun 2020 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| 29th Apr 2020 | TEAS DELETE 1(B) BASIS RECEIVED |
| 29th Apr 2020 | NOTICE OF ALLOWANCE CANCELLED |
| 28th Apr 2020 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| 28th Apr 2020 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| 28th Apr 2020 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| 21st Apr 2020 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 25th Feb 2020 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |